- Home
- SRPT vs DAWN Comparison
SRPT vs DAWN Comparison
Compare SRPT & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRPT | DAWN |
|---|---|---|
| Founded | 1980 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.2B |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SRPT | DAWN |
|---|---|---|
| Price | $22.04 | $21.44 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 28 | 8 |
| Target Price | ★ $25.40 | $24.43 |
| AVG Volume (30 Days) | ★ 3.2M | 2.9M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,198,237,000.00 | $158,182,000.00 |
| Revenue This Year | N/A | $55.03 |
| Revenue Next Year | N/A | $28.12 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 15.58 | ★ 20.60 |
| 52 Week Low | $10.42 | $5.64 |
| 52 Week High | $64.80 | $21.47 |
Technical Indicators
Market Signals| Indicator | SRPT | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 60.58 | 80.95 |
| Support Level | $20.61 | $10.30 |
| Resistance Level | $23.51 | N/A |
| Average True Range (ATR) | 1.43 | 0.05 |
| MACD | 0.41 | -0.36 |
| Stochastic Oscillator | 77.43 | 77.78 |
Price Performance
Historical ComparisonAbout SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.